Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Bioavailability and Bioequivalence of Locally Acting Colon-Targeted Products: In Vivo and In Vitro Considerations"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biopharmaceutics".
Deadline for manuscript submissions: closed (15 October 2021) | Viewed by 8187
Special Issue Editors
grade E-Mail Website
Interests: biopharmaceutics; physiology of the gastrointestinal tract; formulation and modified release; oral drug delivery; colonic targeting; drug metabolism; drug absorption; gamma scintigraphy
2. Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA
Interests: dissolution; disintegration; buffer; oral drug delivery; modified release; biopharmaceutics
Special Issue Information
Targeting drug release to the colon has been a major research topic over the past three decades. Potential applications for colon-targeted products include localized therapy of colonic pathologies (e.g., inflammatory bowel disease and colon cancer). Multiple approaches to colonic delivery exist, such as pH-dependent, microbe-dependent, time-dependent and pressure-dependent drug delivery systems. One of the aspects that sets localized drug delivery apart from systemic drug delivery is the fact that the site of action is located before systemic circulation, making the value of traditional bioavailability and bioequivalence studies questionable. This is sometimes compounded by the poor colonic permeability of many drug substances, resulting in drug release and availability at the site of action being poorly reflected by the drug plasma concentration profile (if observable), which is then shaped by the strong rate-limiting permeation step. Therefore, research into alternative in vivo approaches as well as into in vitro testing methods that exhibit satisfactory in vivo predictivity (preferably without entailing high complexity) is often needed.
Prof. Dr. Abdul Basit
Dr. Jozef Al-Gousous
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- colon targeting
- local drug delivery
- drug release